Literature DB >> 25922427

Regulation of the pharmaceutical industry: promoting health or protecting wealth?

Alan Maynard1, Karen Bloor2.   

Abstract

Mesh：

Year:  2015        PMID： 25922427      PMCID： PMC4480556          DOI： 10.1177/0141076814568299

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  10 in total

1.  Excess in the pharmaceutical industry.

Authors:  Marcia Angell
Journal:  CMAJ       Date:  2004-12-07       Impact factor: 8.262

2.  Are clinical trial data shared sufficiently today? No.

Authors:  Ben Goldacre
Journal:  BMJ       Date:  2013-07-09

3.  What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders?

Authors:  Andrew Lotery; Carrie MacEwen
Journal:  BMJ       Date:  2014-11-18

4.  A clearer view of evidence in treating macular degeneration: off-label policies and independent research.

Authors:  Giulio Formoso; Anna Maria Marata; Nicola Magrini; Lisa Bero
Journal:  Cochrane Database Syst Rev       Date:  2014-09-15

5.  Cancer drugs fund receives boost but will no longer fund "overpriced" drugs.

Authors:  Nigel Hawkes
Journal:  BMJ       Date:  2014-09-01

6.  Using a drug-safety tool to prevent competition.

Authors:  Ameet Sarpatwari; Jerry Avorn; Aaron S Kesselheim
Journal:  N Engl J Med       Date:  2014-04-17       Impact factor: 91.245

7.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

Authors:  Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245

8.  Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.

Authors:  Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan M Downes; Andrew J Lotery; Lucy A Culliford; Barnaby C Reeves
Journal:  Lancet       Date:  2013-07-19       Impact factor: 79.321

Review 9.  Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.

Authors:  Lorenzo Moja; Ersilia Lucenteforte; Koren H Kwag; Vittorio Bertele; Annalisa Campomori; Usha Chakravarthy; Roberto D'Amico; Kay Dickersin; Laurent Kodjikian; Kristina Lindsley; Yoon Loke; Maureen Maguire; Daniel F Martin; Alessandro Mugelli; Bernd Mühlbauer; Isabel Püntmann; Barnaby Reeves; Chris Rogers; Christine Schmucker; Manju L Subramanian; Gianni Virgili
Journal:  Cochrane Database Syst Rev       Date:  2014-09-15

Review 10.  International experience in controlling pharmaceutical expenditure: influencing patients and providers and regulating industry - a systematic review.

Authors:  Iyn-Hyang Lee; Karen Bloor; Catherine Hewitt; Alan Maynard
Journal:  J Health Serv Res Policy       Date:  2014-08-04
  10 in total
  3 in total

1.  The importance of being NICE.

Authors:  Annette Rid; Peter Littlejohns; James Wilson; Benedict Rumbold; Katharina Kieslich; Albert Weale
Journal:  J R Soc Med       Date:  2015-10-02       Impact factor: 5.344

2.  How NICE turned into a Teletubby.

Authors:  Kamran Abbasi
Journal:  J R Soc Med       Date:  2015-06       Impact factor: 5.344

3.  Public health and the legal regulation of the pharmaceutical industry in Algeria.

Authors:  Tareck Alsamara; Ghazi Farouk; Abbaci Adel
Journal:  Pan Afr Med J       Date:  2022-02-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.